This double-blind placebo-controlled paper (n=60) explores the effects psilocybin (12mg/70kg) has on a range of inflammatory markers associated with stress-related psychiatric disorders. Blood samples, MRI and questionnaires were used to assess different aspects of the immune response. Psilocybin immediately reduced levels of the inflammation-inducing TNF-α while other markers were unchanged. After seven days, TNF-α returned to baseline while levels of IL-6 and CRP were reduced in the psilocybin group, which were associated with more persisting positive mood and social effects.
- Published
- Journal
- Brain Behavior and Immunity - Health
- Authors
- Mason, N. L., Szabo, A., Kuypers, K. P. C., Mallaroni, P., de la Torre, R., Reckweg, J., Tse, D. H. Y., Hutten, N. P. W., Ramaekers, J. G.